The RAD CEO more and more kicks Hopper out of control and today marks another proof of what this can do to the funding:
"As part of the partnership, Lantheus will cover all clinical development costs associated with the program."
Time for Hopper to step aside and let people run the company who understand the biotech world when the sun is not always shining. Time to get big pharma and not cap raising sharks involved IF the assets are as good as holders have been told.
IMU Price at posting:
3.6¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)